Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
Abstract readRandomized Controlled Trial
In one paragraph
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Trial
- Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial.Frontiers in immunology · 2026Trial
- Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.The Journal of infectious diseases · 2025Trial
- Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.Nature communications · 2025Trial
- A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Humoral and Cellular Immune Responses Following Bivalent SARS-CoV-2 mRNA Vaccines in Patients Undergoing Hemodialysis: A Prospective Cohort Study.Kidney medicine · 2026Article
- Vaccine Treatment and Evaluation Units: Why Support a "Ready Base" of Clinical Trial Sites?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.The Lancet regional health. Europe · 2025Article
- Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination.PloS one · 2025Article
- Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates.Nature communications · 2024Article
- SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.Journal of virology · 2024Article
- Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography.Nature communications · 2023Article
- T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets.Frontiers in immunology · 2023Review
Corrections and comments
- Update of
Authors and funding
36 authors.
Angela R BrancheDepartment of Medicine, University of Rochester VTEU, Rochester, New York, USA.
Nadine G RouphaelDepartment of Medicine, Emory University Hope Clinic, Decatur, Georgia, USA.ORCID 0000-0002-2512-7919
Cecilia LosadaDepartment of Medicine, Emory University Hope Clinic, Decatur, Georgia, USA.
Lindsey R BadenBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Evan J AndersonCenter for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, Georgia, USA.
Anne F LuetkemeyerZuckerberg San Francisco General, University of California San Francisco, San Francisco, California, USA.
David J DiemertGeorge Washington Vaccine Research Unit, George Washington University, Washington DC, USA.ORCID 0000-0002-2789-0512
Patricia L WinokurDepartment of Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA.
Rachel M PrestiDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Angelica C KottkampDepartment of Medicine, New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) Manhattan Research Clinic at NYU Grossman School of Medicine, New York, New York, USA.
Ann R FalseyDepartment of Medicine, University of Rochester VTEU, Rochester, New York, USA.
Sharon E FreySaint Louis University, Center for Vaccine Development, St. Louis, Missouri, USA.
Richard RuppDepartment of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.
Martín BäckerDepartment of Medicine, NYU VTEU Long Island Research Clinic at NYU Long Island School of Medicine, Mineola, New York, USA.
Richard M NovakDepartment of Medicine, University of Illinois at Chicago-Project WISH, Chicago, Illinois, USA.
Emmanuel B WalterDepartment of Pediatrics, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Lisa A JacksonKaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
Susan J LittleDepartment of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
Lilly C ImmergluckDepartment of Microbiology/Biochemistry/Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA.
Siham M MahgoubDepartment of Medicine, Howard University College of Medicine, Howard University Hospital, Washington DC, USA.
Jennifer A WhitakerDepartments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, Texas, USA.
Tara M BabuDepartments of Medicine, Epidemiology, and Laboratory Medicine & Pathology, University of Washington, Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Paul A GoepfertDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Dahlene N FuscoDepartment of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Robert L AtmarDepartments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, Texas, USA.
Christine M PosavadVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center and Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Antonia NetzlCentre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, United Kingdom.
Derek J SmithCentre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, United Kingdom.
Kalyani TeluThe Emmes Company, LLC, Rockville, Maryland, USA.
Jinjian MuThe Emmes Company, LLC, Rockville, Maryland, USA.
Mat MakowskiThe Emmes Company, LLC, Rockville, Maryland, USA.
Mamodikoe K MakheneDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Sonja CrandonDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
David C MontefioriDepartment of Surgery, Duke University, Durham, North Carolina, USA.
Paul C RobertsDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
John H BeigelDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MStatistical Data Coordinating Center: Monkeypox Clinical Research Support75N93021C00012 · NIAID · THE EMMES COMPANY, LLC · PI EWELL, MARIAN · 2021 to 2025
$150.3MImplementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1MLeadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2MVaccine and Treatment Evaluation Units - DMID 21-0012UM1AI148576 · NIAID · EMORY UNIVERSITY · PI Nadine Georges Rouphael, Carlos del Rio · 2020 to 2026
$41.7MEstablishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012UM1AI148574 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Angelica Cifuentes Kottkamp, Anoma Nellore · 2020 to 2026
$23.9MUniversity of Rochester Vaccine and Treatment Evaluation Unit (VTEU)-mRNA-1273-P204 Moderna Pediatric StudyUM1AI148450 · NIAID · UNIVERSITY OF ROCHESTER · PI Angela Ramona Branche, Ann R Falsey · 2020 to 2026
$20.6MTargeting distinct DNA methylation signatures in pediatric glioma using HITMA75N91022C00007 · NCI · NZUMBE EPIGENETICS · PI ROUNTREE, MICHAEL · 2022 to 2022
$355kNCATS NIH HHS UL1 TR002378NCI NIH HHS 75N91019D00024NCI NIH HHS 75N91022C00007NIAID NIH HHS 75N93021C00012NIAID NIH HHS UM1 AI148450NIAID NIH HHS UM1 AI148574NIAID NIH HHS UM1 AI148576NIAID NIH HHS UM1 AI148684
Abstract
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
Indexed as
COVID-19Antibodies, NeutralizingAntibodies, ViralHumansSARS-CoV-2Vaccines, CombinedAntibodies, NeutralizingAntibodies, ViralVaccines, CombinedSARS-CoV-2vaccinevariant
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.